Acyl-coenzyme A synthetase medium chain family member 1 (ACSM1) may be a novel biomarker for prostate cancer screening and diagnosis, metastasis monitoring, and outcome prediction. Creative Biolabs is a facilitator in biomarker analysis, assay development, biomarker discovery. We offer ACSM1 analysis services for academic validation in sample collections and biobanks in different indication areas.
Fig.1 Illustration of fatty acid metabolic pathways.1
Background
ACSM1 is a medium chain acyl-CoA synthetase family member and plays an important role in fatty acid metabolism. Genomic copy number alterations of ACSM1, including deletion, amplification, and amino acid changes were frequently observed in prostate cancer. ACSM1 is significantly and specifically upregulated in prostate cancer. ACSM1 gene expression and genomic amplification exhibit clinical significance through metabolic and ECM-receptor interaction signaling pathways. Therefore, ACSM1 presents to be an oncogene and serve as a biomarker for prostate cancer screening, prognosis prediction, and as a therapeutic target.
Increase Your Chance for Paramount Discoveries
Creative Biolabs utilizes the latest advancements in diagnostic testing to offer an extensive line of specialized biomarker analysis. Firstly, ACSM1 ELISA assay is generally performed for the in vitro quantitative measurement of human ACSM1 concentrations in tissue homogenates, cell lysates, and other biological fluids. Besides, epidemiological studies have shown the association between genomic alterations and metastasis, extremely DNA copy number variants or alterations in ACSM1 gene deletions, amplifications, or mutations in tumor tissues that had strong association with prostate cancer progression. Creative Biolabs provides the following customized services for global clients to support your research.
| Cat | Service |
| BAS70-1 | ACSM1 Protein Expression Analysis |
| BAS70-2 | Gene Mutation and Genomic Alteration Analysis |
| BAS70-3 | ACSM1 Branched DNA Gene Expression Assays |
Our wide variety of technology platforms allow Creative Biolabs to choose the right technology for your biomarker. No matter how complex the assay, our team has the scientific and regulatory expertise to measure your biomarker and to ensure delivery of quality results on time. Please don't hesitate to contact us today to develop custom solution for specific needs. We will work to accommodate your request.
Reference
- Wu, Zhimin, et al. "An update on the therapeutic implications of long-chain acyl-coenzyme A synthetases in nervous system diseases." Frontiers in Neuroscience 16 (2022): 1030512. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.
